Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Trial Profile

Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Anal cancer; Carcinoid tumour; Carcinoma; Cervical cancer; Endometrial cancer; Mesothelioma; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms KEYNOTE-028; MK-3475-028/KEYNOTE-28
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 20 Mar 2018 Results (n=25) assessing safety and antitumor activity of pembrolizumab in the ER+/HER2 advanced breast cancer cohort of this study, were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 16 Feb 2018 Planned primary completion date changed from 13 Jul 2018 to 28 Sep 2018.
    • 24 Jan 2018 Planned End Date changed from 13 Jul 2018 to 28 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top